A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and examines potential avenues for future research, including androgen ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

PURPOSECombining radiotherapy with androgen deprivation therapy (ADT) is recommended for localized prostate cancer. However, the time required for significant therapeutic benefits is not well ...

A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT. Androgen deprivation therapy (ADT) is ...

Androgen-deprivation therapy (ADT) entails lowering serum testosterone levels to castrate levels and forms a cornerstone of the management of hormone-sensitive advanced prostate cancer; however, the ...